圣犹达终身队列研究(SJLIFE)中女性儿童癌症幸存者的后续乳腺癌
在圣犹达终身队列中,1467名女性儿童癌症幸存者中56人发生68例乳腺癌,中位年龄38.6岁。胸部放疗≥20 Gy、蒽环类累积剂量≥250 mg/m2及乳腺癌易感基因突变均与风险升高相关。影像筛查发现的乳腺癌分期更早、更少需要化疗。
要点
- 胸部放疗≥20 Gy者乳腺癌风险为无放疗者的7.6倍(HR 7.6,95%CI 2.9–20.4)。
- 蒽环类≥250 mg/m2者风险为未暴露者的13.4倍(HR 13.4,95%CI 5.5–32.5)。
- 携带乳腺癌易感基因突变者风险为无突变者的23.0倍(HR 23.0,95%CI 7.3–72.2)。
核心结论
- 较高剂量蒽环类与乳腺癌风险升高相关,且独立于已知癌症易感基因突变。
- 影像筛查发现的乳腺癌较体格检查发现者更少需要化疗。
研究设计与样本
- 圣犹达终身队列研究(SJLIFE),女性参与者接受基于风险的评估、既往健康事件验证、胸部放疗剂量测定和全基因组测序。
- 共纳入1467名女性,其中139人亚组同时接受乳腺磁共振成像和钼靶检查。
- 采用多因素回归计算风险比(HR)和95%置信区间(CI)。
主要发现
- 1467名女性中56人发生68例乳腺癌,中位年龄38.6岁(范围24.5–53.0岁)。
- 35岁时乳腺癌累积发病率:无胸部放疗者1%,胸部放疗≥10 Gy者8%。
- 调整模型中,胸部放疗≥20 Gy vs 无放疗:HR 7.6(95%CI 2.9–20.4)。
- 蒽环类暴露 vs 无暴露:1–249 mg/m2者HR 2.6(95%CI 1.1–6.2),≥250 mg/m2者HR 13.4(95%CI 5.5–32.5)。
- 携带乳腺癌易感基因突变 vs 无突变:HR 23.0(95%CI 7.3–72.2)。
关键数值与推荐
- 胸部放疗≥20 Gy vs 无放疗:HR 7.6(95%CI 2.9–20.4)。
- 蒽环类1–249 mg/m2 vs 无暴露:HR 2.6(95%CI 1.1–6.2)。
- 蒽环类≥250 mg/m2 vs 无暴露:HR 13.4(95%CI 5.5–32.5)。
- 乳腺癌易感基因突变 vs 无突变:HR 23.0(95%CI 7.3–72.2)。
- 35岁累积发病率:无胸部放疗1%,胸部放疗≥10 Gy 8%。
临床怎么用
- 对儿童癌症女性幸存者进行基于风险的评估,包括胸部放疗剂量测定和基因检测。
- 对高风险幸存者采用乳腺磁共振成像联合钼靶进行监测筛查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Anthracycline-associated risk for subsequent breast cancer in childhood cancer survivors is hypothesized to be mediated by TP53 mutation-related gene-environment interactions. We characterized treatment/genetic risks and the impact of screening for breast cancer in the St Jude Lifetime Cohort. PATIENTS AND METHODS: Female participants underwent risk-based assessments, prior health event validation, chest radiation dosimetry, and whole genome sequencing. Breast biopsy reports were reviewed. A subgroup (n = 139) underwent both breast magnetic resonance imaging and mammography. Multivariable regression was used to calculate hazard ratios (HRs) and 95% CIs. RESULTS: Among 1,467 women, 56 developed 68 breast cancers at a median age 38.6 (range, 24.5 to 53.0) years. Cumulative incidences at age 35 years were 1% (no chest radiation) and 8% (≥ 10 Gy of chest radiation). In adjusted models, breast cancer was associated with 20 Gy or more of chest radiation versus none (HR, 7.6; 95% CI, 2.9 to 20.4), anthracycline exposure versus none (1 to 249 mg/m2: HR, 2.6; 95% CI, 1.1 to 6.2; ≥ 250 mg/m2: HR, 13.4, 95% CI, 5.5 to 32.5), and having a breast cancer predisposition gene mutation (HR, 23.0; 95% CI, 7.3 to 72.2). Anthracyclines 250 mg/m2 or greater remained significantly associated with increased risk of breast cancer in models excluding survivors with cancer predisposition gene mutations, chest radiation 10 Gy or greater, or both. Sensitivity/specificity were 53.8%/96.3% for mammography, 69.2%/91.4% for magnetic resonance imaging, and 85.8%/99.7% for dual imaging. Breast cancers detected by imaging and/or prophylactic mastectomy compared with physical findings were more likely to be in situ carcinomas, smaller, without lymph node involvement, and treated without chemotherapy. CONCLUSION: Higher doses of anthracyclines are associated with increased risk of breast cancer independent of mutations in known cancer predisposition genes. Surveillance imaging identifies breast cancers less likely to require chemotherapy than those detected by physical findings.
引用
- Ehrhardt MJ, Howell CR, Hale K, et al. Subsequent Breast Cancer in Female Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE). J Clin Oncol. 2019. PMID: 31075046. doi:10.1200/JCO.18.01099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。